Not yet taking people in SwitzerlandNo phase
Follows adults with IgA nephropathy who take sparsentan in Switzerland
Observes how kidney disease changes in adults with IgA nephropathy receiving sparsentan.
Plain-language title generated from the registry record
Registry title: Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
Key facts
- Where
- Zurich, SwitzerlandSee the site
Where in Switzerland
- Stadtspital ZürichZurich, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Waid City Hospital, Zurich
- Trial code
- NCT07555301
- Record updated
- 29 April 2026
- Original description
An observational study tracking the clinical course of patients with IgA nephropathy.Read full original descriptionShow less
Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
An observational study tracking the clinical course of patients with IgA nephropathy.
Inclusion: IgA Nephropathy, Use of Sparsentan.
Exclusion: age < 18y.